Laurus Labs’ Performance Analyzed

Key Points

• Net profit soared 882% to ₹194.97 crore in Q2 FY26.
• Revenue jumped 33% to ₹3,223.04 crore.
• CDMO services grew by 53% to ₹518 crore.
• EBITDA increased 136% to ₹429 crore.
• Margins improved to 26%, supported by efficient operations.
• The company invested in new technologies & strategic partnerships.

Laurus Labs had a really strong quarter! Their profits grew dramatically, jumping by a huge 882%. This means they made significantly more money than they did last year. This growth was driven by increased sales and a smarter approach to their business.

The company’s total revenue climbed by 33% to ₹3,223.04 crore. This growth was fueled by expanding CDMO services—essentially helping other companies make medicines—which jumped by 53% to ₹518 crore. This shows they’re becoming a key partner for other drug makers.

Laurus Labs also saw a big boost in their EBITDA—the money they make after paying for the main costs of running the business. It grew by 136% to ₹429 crore. This demonstrates how efficiently they’re managing their operations and generating profit.

Their EBITDA margin—the percentage of revenue that becomes profit—also improved to 26%. This means they’re getting a better return on each sale. The company’s leaders are focused on making smart choices to keep their profits rising.

The company’s founder, Satyanarayana Chava, highlighted their leadership in creating medicines for diseases like HIV, and that they are making great progress in supporting other companies. They’ve also invested in new technologies and partnered with other companies to improve their services.

V V Ravi Kumar, the company’s CFO, noted that their strong performance is due to steady growth in CDMO and Generic businesses. They achieved revenues of ₹1,653 crore and EBITDA of ₹429 crore. They’ve also managed to reduce their debt, making the company financially healthy.

Laurus Labs rewarded shareholders with an interim dividend of ₹0.80 per share. This is a small payment to thank investors for their support. The company is committed to continued growth and innovation, investing in promising new technologies and expanding their capabilities.

Ultimately, Laurus Labs is a company dedicated to creating better medicines and supporting other companies in doing the same.